Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marybeth Rivard

Nurse Practitioner, Adult Health Columbus, OH Nurse Practitioner

NPI 1174507487 CMS profile 10979977

NP Care LLC, Six Corporate Dr Suite 420, Columbus, OH 43204

Open in the dashboard

General payments

$41,099

226 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marybeth Rivard of Columbus, OH is reported in the CMS Open Payments database as having received $41,099 across 226 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $647 26
2024 General $38,559 108
2023 General $1,148 53
2022 General $676 35
2021 General $69 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marybeth Rivard
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Marybeth Rivard were reported at $647. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Marybeth Rivard Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $69 $138 $43–$438 $132
2022 $676 $165 $54–$494 $149
2023 $1,148 $178 $61–$549 $160
2024 $38,559 $186 $62–$575 $164
2025 $647 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $38,485 100 payments
  2. ViiV Healthcare Company $1,440 71 payments
  3. Janssen Biotech, Inc. $268 15 payments
  4. Merck Sharp & Dohme Corporation $210 9 payments
  5. Lilly USA, LLC $181 7 payments
  6. Napo Pharmaceuticals Inc $171 6 payments
  7. AbbVie, Inc. $118 6 payments
  8. Novo Nordisk Inc $66 4 payments
  9. Antares Pharma, Inc. $44 2 payments
  10. Theratechnologies Inc. $40 2 payments
  11. Other $76 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,276 15 payments
  2. Travel and Lodging $9,977 22 payments
  3. Food and Beverage $5,115 186 payments
  4. Consulting Fee $3,720 2 payments
  5. Education $11 1 payment
Products named General payments · program years 2021–2025
  1. Descovy $12,424 20 payments
  2. Biktarvy $4,564 9 payments
  3. DOVATO $534 29 payments
  4. APRETUDE $433 20 payments
  5. SYMTUZA $268 15 payments
  6. CABENUVA $263 13 payments
  7. DELSTRIGO $210 9 payments
  8. PIFELTRO $199 8 payments
  9. Mytesi $171 6 payments
  10. JARDIANCE $105 2 payments
  11. Other $777 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

1,663

Median for Nurse Practitioner: 389

Drug cost

$653,264

Median for Nurse Practitioner: $21,885

Branded share of claims

29.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 72 $259,667
Juluca Dolutegravir/Rilpivirine Brand 28 $95,570
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 23 $87,268
Dovato Dolutegravir Sodium/Lamivudine Brand 23 $63,363
Tivicay Dolutegravir Sodium Brand 15 $33,315
Prezcobix Darunavir/Cobicistat Brand 13 $31,480
Ozempic Semaglutide Brand 26 $19,878
Rexulti Brexpiprazole Brand 16 $16,532
Qulipta Atogepant Brand 13 $9,784
Imvexxy Estradiol Brand 11 $8,725

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Descovy
  • Gilead Sciences, Inc. $12,424
$12,424 — —
Biktarvy
  • Gilead Sciences, Inc. $4,564
$4,564 72 —
APRETUDE
  • ViiV Healthcare Company $195
$195 — —
DOVATO
  • ViiV Healthcare Company $133
$133 23 —
CABENUVA
  • ViiV Healthcare Company $126
$126 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record